Serial No.: 10/577,382 Filed: April 27, 2006

Page 2

## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Original) A method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to thereby reduce the extent of neuronal damage in the subject.
- 2. (Original) The method of claim 1, wherein the subject is a human.
- 3. (Original) The method of claim 1, wherein the neuronal damage comprises cell death in the hippocampus and/or cerebral cortex.
- 4. (Original) The method of claim 1, wherein the neuronal damage comprises cell dysfunction in the hippocampus and/or cerebral cortex.
- 5. (Original) The method of claim 1, wherein the inhibitor is an antibody which, when contacted with RAGE, specifically inhibits binding between RAGE and a ligand thereof.
- 6. (Original) The method of claim 1, wherein the inhibitor is an

Serial No.: 10/577,382 Filed: April 27, 2006

Page 3

anti-sense molecule which specifically inhibits the expression of RAGE in a cell.

- 7. (Original) The method of claim 1, wherein the inhibitor is an RNAi molecule which specifically inhibits the expression of RAGE in a cell.
- 8. (Original) The method of claim 1, wherein the inhibitor is a catalytic nucleic acid which specifically inhibits the expression of RAGE in a cell.
- 9. (Original) The method of claim 1, wherein the inhibitor is administered during the seizure.
- 10. (Original) The method of claim 1, wherein the inhibitor is administered within three days of the seizure.
- 11. (Original) The method of claim 1, wherein the inhibitor is administered within one day of the seizure.
- 12. (Original) The method of claim 1, wherein the inhibitor is administered within six hours of the seizure.
- 13. (Original) The method of claim 1, wherein the inhibitor is administered within one hour of the seizure.
- 14. (Original) The method of claim 1, wherein the inhibitor is administered within 20 minutes of the seizure.
- 15. (Original) A method for inhibiting neuronal damage which would

Serial No.: 10/577,382
Filed: April 27, 2006

Page 4

otherwise result from a seizure in a subject predisposed to having a seizure, comprising administering to the subject a prophylactically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to inhibit neuronal damage which would otherwise result from a seizure in the event the subject were to suffer a seizure.

- 16. (Original) The method of claim 15, wherein the subject is human.
- 17. (Original) The method of claim 15, wherein the neuronal damage comprises cell death in the hippocampus and/or cerebral cortex.
- 18. (Original) The method of claim 15, wherein the neuronal damage comprises cell dysfunction in the hippocampus and/or cerebral cortex.
- 19. (Original) The method of claim 15, wherein the inhibitor is an antibody which, when contacted with RAGE, specifically inhibits binding between RAGE and a ligand thereof.
- 20. (Original) The method of claim 15, wherein the inhibitor is an anti-sense molecule which specifically inhibits the expression of RAGE in a cell.
- 21. (Original) The method of claim 15, wherein the inhibitor is an RNAi molecule which specifically inhibits the expression of RAGE in a cell.

Serial No.: 10/577,382 Filed: April 27, 2006

Page 5

- 22. (Original) The method of claim 15, wherein the inhibitor is a catalytic nucleic acid which specifically inhibits the expression of RAGE in a cell.
- 23. (Canceled)
- 24. (Canceled)
- 25. (New) An article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to treat a subject during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure.
- 26. (New) An article of manufacture comprising (a) a packaging material having therein an inhibitor of receptor for advanced glycation endproducts (RAGE) and (b) instructions for using the inhibitor to inhibit neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure.